Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04208620 | Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus | PHASE1 | COMPLETED | 16 | — | — | Jan 21, 2020 | Jul 8, 2020 | Jul 31, 2020 | 3 | Japan |
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
To assess the safety and tolerability of Cotadutide
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo administered subcutaneously |
| Cotadutide | EXPERIMENTAL | Cotadutide administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo administered subcutaneously |
| Cotadutide | DRUG | Cotadutide administered subcutaneously |
Inclusion Criteria 1. Provision of signed and dated written informed consent prior to any mandatory study specific procedures, sampling, and analyses. 2. Subject must be 20 to 74 years of age at screening. 3. HbA1c range of 6.5% to 8.5% at screening and run-in visit. 4. Willing and able to self-inj...